Jubilant Pharmova's net loss widened sequentially to ₹97.84 crore in the quarter ending March 31, 2023, period. In the preceding quarter, the company posted a loss of ₹15.67 crore. However, Jubilant posted a loss against a profit of ₹59.55 crore that was recorded in Q4FY22.
Profitability was impacted as total expenses in Q4FY23 shoot up drastically. In the quarter, total expenses stood at ₹1,785.57 crore versus ₹1,420.24 crore in Q4FY22 and ₹1,551.69 crore in Q3 of FY23.
Also, the company posted an exception items loss of ₹86.41 crore in the March 2023 quarter.
EBITDA also came in at ₹202.1 crore in the quarter under review, declining by 13.7% from ₹234.2 crore in Q4 of FY22. Similarly, EBITDA margins dipped to 12.2% in Q4 FY23, as against 15.5% in the same quarter last year.
However, the company recorded growth in terms of revenue from operations to ₹1,678 crore in Q4FY23, as against ₹1,552.51 crore in Q3FY23 and ₹1,527.53 crore in Q4FY22.
For the full year FY23, the revenue was at ₹6,281.73 crore compared to ₹6,130.16 crore in FY22. Meanwhile, the company saw a loss of ₹648.88 crore in FY23 as against a profit of ₹413.02 crore in FY22.
Despite net loss in FY23, in a meeting held on Monday, Jubilant's board of directors declared a dividend of ₹5 per share having a face value of Re 1 each for the fiscal FY23.
The dividend, if approved by the shareholders at the ensuing Annual General Meeting of the company, then will be paid/dispatched within 30 days from the date of AGM.
On BSE, Jubilant Pharmova's share price closed at ₹357.75 apiece down by 1.4%. The stock was near its day's low of ₹355.65 apiece.
Catch all the Business News , Market News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.